Reshaping the HIV treatment and prevention landscape
A robust late-stage pipeline with FiC or BiC potential
and more than £20bn in NRA PYS potential
Asset
Next indication(s)
Cabotegravir
HIV PrEP*
daprodustat
Blenrep
Anaemia in CKD
Multiple myeloma earlier lines
Jemperli^^^
1L endometrial cancer
gepotidacin
RSV^
Men ABCWY^
otilimab
uUTIs
Older adults /other**
Meningitis
Rheumatoid arthritis
1L ovarian cancer with dostarlimab
Zejula
depemokimab ('294)
Asthma
HBV ASO ('836)
Hepatitis B
gsk
Potential first- or
Best-in-class
Major Lifecycle
Innovation
NRA PYS range
Anticipated
submission
>£2bn
2021
£0.5-1bn
2022
>£3bn
2022
₤1-2bn
2022
£0.5-1bn
2023^^
>£3bn /£1-2bn
2023
₤1-2bn
2023
₤1-2bn
2023
>₤2bn
2024
₤1-2bn
2024
>£2bn
2025
Pipeline sales potential based on non-risk adjusted peak year sales. See basis of preparation and assumptions in Appendix
*PYS range includes treatment (approved, Cabenuva) and PrEP; maternal and paediatric
**
^ denotes vaccine candidate; For RSV initial data, timing dependent on RSV infection circulation during pandemic lockdowns; ^^ Interim analysis in 2022, subject to regulators feedback; ^^^ NRA PYS includes 1L EC & OC, Tesaro asset
51View entire presentation